This trial will test a new treatment for diseases caused by the Epstein-Barr virus.
1 Primary · 7 Secondary · Reporting Duration: Up to 2 years
Experimental Treatment
228 Total Participants · 6 Treatment Groups
Primary Treatment: Tabelecleucel · No Placebo Group · Phase 2
Age Any Age · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Michigan | 100.0% |
65+ | 100.0% |
Cleveland Clinic Taussig Cancer Center (Adults and Pediatrics) | 100.0% |
Met criteria | 100.0% |